[Myelodepression during antitumor therapy in hepatorenal insufficiency].
The hematotoxicity of cytostatics was found enhanced if these agents were used in therapy of oncologic patients with disordered functional activity of the hepatorenal system. Decreased absorption and excretory functions of the hepatocytes or renal abnormalities associated with impaired glomerular filtration and secretory-excretory function are the factors that contribute to the development of leukopenia by the middle or end of the treatment course. This permits a conclusion on the prognostic value of examinations of liver and kidney function in cases with the development of secondary hemodepression in chemotherapy of oncologic patients.
Moskalenko
I P
IP
Gaĭseniuk
L A
LA
Vasil'ev
L Ia
LIa
Ronin
V S
VS
Nikiforova
N A
NA
Timchenko
V G
VG
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D007970:Leukopenia / Q000139:chemically induced*; D008099:Liver / Q000503:physiopathology*; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology*
D000970:Antineoplastic Agents
Mielodepressiia v protsesse protivoopukholevoĭ terapii pri gepatorenal'noĭ nedostatochnosti.